Therapy
Biotechnology
Health

Exelixis

$21.27
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.86 (-3.89%) Today
$0.00 (0.00%) As of 5:05 PM EDT after-hours

Why Robinhood?

You can buy or sell Exelixis and other stocks, options, ETFs, and crypto commission-free!

About EXEL

Exelixis, Inc. Common Stock, also called Exelixis, is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. Read More It offers products under the brands of Cometriq, Cabometyx, and Cotellic. The company was founded by Corey S. Goodman and Stelios B. Papadopoulos on November 15, 1994 and is headquartered in South San Francisco, CA.

Employees
484
Headquarters
Parkway Alameda, California
Founded
1994
Market Cap
6.41B
Price-Earnings Ratio
10.23
Dividend Yield
0.00
Average Volume
1.99M
High Today
$22.25
Low Today
$21.22
Open Price
$22.14
Volume
2.39M
52 Week High
$25.31
52 Week Low
$13.42

Collections

Therapy
Biotechnology
Health
Cancer Prevention
Pharmaceutical
Biopharmaceutical
Medical
Technology

EXEL News

Yahoo FinanceJun 24

Read This Before You Buy Any New Cancer Drug Stocks

825
Yahoo FinanceJun 21

Oh, By the Way, This Clinical Trial Didn't Work

437
ReutersJun 20

BRIEF-Exelixis Says No New Safety Signals Were Identified With Combination Of Cobimetinib And Atezolizumab

185

EXEL Earnings

$0.12
$0.22
$0.31
$0.41
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
Actual
Available Jul 31, After Hours

Popular Stocks

More EXEL News

Yahoo FinanceJun 20

Here’s What Hedge Funds Think About Exelixis, Inc.

25
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.